***Background.*** Methicillin-Resistant *Staphylococcus aureus* (MRSA) is a major problem in the healthcare setting. Bloodstream infections caused by MRSA is an important reason of mortality. Vancomycin and teicoplanin are used for many years in the treatment of MRSA. In contrast, daptomycin is one of the novel options. In this study, in-vitro activity of daptomycin was compared to vancomycin and teicoplanin against MRSA strains isolated from blood cultures.

***Methods.*** The identification of the MRSA isolates was based on conventional microbiological methods and an additional automated identification system (*VITEK*®*2*, bioMerieux, France). A total of 200 MRSA clinical isolates were included in the study. Daptomycin, vancomycin, and teicoplanin susceptibility were investigated by E-test (AB bioMerieux, Sweden). E-test was performed according to the instructions of the manufacturer. Susceptibilities of the strains to daptomycin, vancomycin, and teicoplanin were performed using the E-test according to the recommendations of CLSI 2013/EUCAST 2014 and the manufacturer.

***Results.*** The MIC ranges were 0.25-1 µg/ml for daptomycin, 1.5-6 µg/ml for vancomycin, and 2-16 µg/ml for teicoplanin. Daptomycin was found to exhibite a good activity.

***Conclusion.*** According to MIC values, daptomycin seems 6 times more effective than vancomycin and 8-16 times more effective than teicoplanin. With having the lowest MIC values, daptomycin may represent a therapeutic option for the infections caused by MRSA.
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